How Low Should Blood Pressure Go? Inside the "Great Scam" Debate
A viral video claimed the push for ever-lower blood pressure targets is a "scam," citing a 2022 Cochrane review that found no mortality benefit below 135/85. This analysis walks through what the review actually shows, why relative and absolute risk both matter, and why the cardiovascular-events result sits right on the edge of significance. The honest conclusion: the data are not conclusive yet, and gentler, non-pharmaceutical routes to lower pressure remain the prudent path.
Overview
The episode opens with a challenge: after covering the SPRINT trial — which suggested pushing blood pressure below 120/80 beats a 140/90 target in people with cardiovascular disease — the channel was flooded with comments citing a Cochrane review that seemed to say the opposite. That review, published in 2022, pooled seven randomised trials and roughly 9,600 participants comparing a lower target (under 135/85) with the older standard (140–160 over 90–100).
Its headline finding: no detectable benefit for total mortality, cardiovascular mortality, cardiovascular events or serious adverse events. Dr. Boz's read of the bias assessments, the pharmaceutical funding of two trials and SPRINT's early stopping is presented and then carefully contextualised — a bias score measures the potential for bias, not proven bias, and stopping a trial early can be an ethics-board decision rather than a scandal.
The clearest teaching moment is the relative-versus-absolute risk explanation: absolute risk looks tiny in a three-year snapshot, but it compounds over the decades a cardiovascular disease actually takes to unfold, so dismissing it as "only 0.1%" misinforms. Three levers govern whether a trial can see an effect at all — duration, effect size and sample size — and here all three were squeezed: an average follow-up of about 3.5 years, a target gap of only five units, and a subgroup analysis that shed over 70% of the sample.
Crucially, the cardiovascular-events outcome came within a hair of statistical significance, and newer trials the reviewers themselves flagged as ongoing point in the direction of benefit. Mortality lags behind events for a simple reason: far more people have a heart attack than die from one, so the mortality data carry less statistical power. The closing position is deliberately unsensational — the analysis genuinely differs from SPRINT, but it is not the final word.
Key quotes
5I'm not arguing that. Nobody's arguing that. What the question we're asking is how low should we push it.
That is not what I'm saying. I am saying how low should we treat it to, and why.
Absolute risk might be tiny initially, but the absolute risk tends to increase as time passes.
We cannot state these results are conclusive.
Opting for lower blood pressure, especially through non-pharmaceutical means, is likely the more prudent way to go right now.
Key ideas
9The clash: SPRINT versus Cochrane
SPRINT suggested a sub-120/80 target outperforms 140/90 in people with cardiovascular disease. A 2022 Cochrane review pooling seven trials found no such benefit below 135/85, which is what sparked the "scam" framing.
Nobody disputes that high pressure matters
Both sides agree hypertension is a leading preventable driver of stroke, heart attack and heart failure. The open question is purely how far down the target should be pushed, and at what cost.
Bias scores measure potential, not proof
Standardised checklists flag conditions that could introduce bias — industry funding, early stopping — rather than demonstrating that a study was distorted. None of the trials could be placebo-controlled, because withholding treatment from cardiovascular patients would be unethical.
Stopping early cuts both ways
SPRINT was halted before its planned endpoint, which is technically a source of bias. In context it reflected an ethics board acting on a consistent, obvious effect rather than any attempt to manipulate the result.
Relative risk versus absolute risk
A 26% relative increase can correspond to a move from 30 to 38 cases per 10,000 — an absolute difference under a tenth of a percent. Both numbers are true, and reporting only one distorts the picture.
Absolute risk is bounded by time
A three-year trial captures only a snapshot. Because cardiovascular risk compounds across decades, treating a small absolute number as permanently small is one of the most common analytical errors in health commentary.
What the review actually found
Total mortality landed at a relative risk of about 1.05, with confidence intervals straddling one. Serious adverse events, cardiovascular mortality and cardiovascular events likewise showed no clear separation between the two targets.
Three levers decide what a trial can see
Duration, effect size and sample size determine whether a real effect becomes detectable. Here follow-up averaged around 3.5 years, the target gap was only five units, and the subgroup analysis kept under 30% of the original sample.
Events versus mortality: a power problem
Far more people survive a heart attack than die from one, so mortality endpoints collect fewer data points and carry less statistical power. That alone can explain a signal in events without a matching signal in deaths.
Practical takeaways
6- 1
Don't change medication off a video 2:30
Both the original presenter and the analysis explicitly warn against treating this debate as a reason to stop or reduce prescribed treatment. Any change belongs in a conversation with your own doctor.
- 2
Always ask for both risk numbers 9:20
When a headline gives a percentage change, look for the underlying counts per thousand or per ten thousand. Relative risk without absolute risk — or the reverse — is half a story.
- 3
Put the time horizon on the risk 11:00
Ask how long the trial ran before deciding whether a small absolute risk is reassuring. A three-year figure says little about a condition that develops across thirty years.
- 4
Adherence shapes the result 16:00
Only about 64% of the intensive group hit their target, versus far more in the standard group. When one arm takes its medication more consistently, comparisons between them get harder to read.
- 5
Treat "not significant" as a spectrum 20:00
A p-value sitting at 0.05 is a hair from the conventional threshold, not evidence of no effect. Watch for follow-up trials before treating a near-miss as a settled answer.
- 6
Favour the non-pharmaceutical levers first 26:00
Where lower pressure can be reached through lifestyle rather than stacking additional medications, that route avoids the adverse events and withdrawals seen in the intensive arms.
Topics & chapters
16Why this video exists
The comment flood after the SPRINT analysis, and the viral video that triggered it. The plan: hear the argument out, then add context.
Common ground on hypertension
High blood pressure as a leading preventable cause of premature death and disability. The disagreement is about targets, not importance.
What the Cochrane review asked
Does a target under 135/85 reduce mortality or morbidity compared with the older 140–160 over 90–100 standard, in people with existing cardiovascular disease?
A warning about medication
An explicit disclaimer that none of this is a reason to stop treatment. The question under discussion is where to aim, not whether to treat.
Reading the bias assessments
Industry funding in two trials, early termination in another, and no placebo arms anywhere. What these flags do and do not tell us.
Why SPRINT stopped early
Ethics boards can halt a trial when the effect is obvious and continuing standard treatment becomes hard to justify.
The breast cancer risk example
Thirty versus thirty-eight cases per ten thousand, reported as a 26% increase. A clean illustration of how relative framing lands differently.
Where absolute risk misleads
Absolute risk is constrained by trial length. Over decades, a number that looked negligible grows into something that matters.
Total mortality across seven trials
A pooled relative risk near 1.05 with intervals crossing one. Deaths are the cleanest endpoint to count, and they showed no separation.
Cardiovascular events and adverse effects
Fourteen fewer events per thousand in the lower-target group, alongside more withdrawals driven by adverse effects in that same arm.
The conclusions Dr. Boz draws
More medications needed, no mortality benefit detected, and a genuine downside in adverse events among those pushed lowest.
Adherence and the five-unit gap
Only about 64% of the intensive group reached target, and the two targets differed by just five units — both of which shrink any detectable difference.
The three levers of trial design
Time, effect size and sample size. Cardiovascular disease unfolds over decades while these trials averaged roughly 3.5 years.
The near-miss on cardiovascular events
A p-value right at 0.05, plus ongoing trials the reviewers themselves listed — two of which already point toward benefit.
Why events move before deaths
Surviving a heart attack is common, so mortality data accumulate slowly and lose statistical power relative to event data.
The measured takeaway
The analysis genuinely differs from SPRINT, but it is not conclusive. Lower pressure through non-pharmaceutical routes remains the prudent bet.